Commercial insulin immunoassays fail to detect commonly prescribed insulin analogues

Clinical Biochemistry

Volumn 48, Issue 18, 2015, Pages 1354-1357

  Parfitt, C ^a   Church, D ^b,c   Armston, A ^d   Couchman, L ^e   Evans, C ^f   Wark, G ^g   McDonald, T J ^a,h  

^a Royal Devon and Exeter Foundation Hospital   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

^f UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^g ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^h UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

Analogues; Cross reactivity; Hypoglycaemia; Immunoassay; Insulin

Indexed keywords

C PEPTIDE; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; NEUTRAL INSULIN; SYNTHETIC INSULIN; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; PRESCRIPTION DRUG;

ARTICLE; CLINICAL LABORATORY; CONTROLLED STUDY; CROSS REACTION; DIFFERENTIAL DIAGNOSIS; HUMAN; HYPOGLYCEMIA; IMMUNOASSAY; IMMUNOASSAY ANALYZER; MASS SPECTROMETRY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; UNITED KINGDOM; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; CHEMISTRY; METABOLISM; SENSITIVITY AND SPECIFICITY; STANDARDS;

ANTIBODIES, MONOCLONAL; BIOMARKERS; C-PEPTIDE; CROSS REACTIONS; HUMANS; HYPOGLYCEMIA; IMMUNOASSAY; INSULIN; PRESCRIPTION DRUGS; SENSITIVITY AND SPECIFICITY;

EID: 84949087486     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2015.07.017     Document Type: Article

References (16)

1. Brackenridge A., Wallbank H., Lawrenson R.A., Russell-Jones D. Emergency management of diabetes and hypoglycaemia. Emerg. Med. J. 2006, 23(3):183-185.
2. Marks V., Teale J.D. Investigation of hypoglycaemia. Clin. Endocrinol. 1996, 44(2):133-136.
3. Marks V., Wark G. Forensic aspects of insulin. Diabetes Res. Clin. Pract. 2013, 101(3):248-254.
4. Teale J.D., Wark G., Marks V. The biochemical investigation of cases of hypoglycaemia: an assessment of the clinical effectiveness of analytical services. J. Clin. Pathol. 2002, 55(7):503-507.
5. Green R.P., Hollander A.S., Thevis M., Thomas A., Dietzen D.J. Detection of surreptitious administration of analog insulin to an 8-week-old infant. Pediatrics 2010, 125(5):e1236-e1240.
6. Neal J.M., Han W. Insulin immunoassays in the detection of insulin analogues in factitious hypoglycemia. Endocr. Pract. 2008, 14(8):1006-1010.
7. Holden S.E., Poole C.D., Morgan C.L., Currie C.J. Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin. BMJ Open 2011, 1(2):e000258.
8. Owen W.E., Roberts W.L. Cross-reactivity of three recombinant insulin analogs with five commercial insulin immunoassays. Clin. Chem. 2004, 50(1):257-259.
9. Heald A.H., Bhattacharya B., Cooper H., Ullah A., McCulloch A., Smellie S., et al. Most commercial insulin assays fail to detect recombinant insulin analogues. Ann. Clin. Biochem. 2006, 43(Pt 4):306-308.
10. Sapin R., Le Galudec V., Gasser F., Pinget M., Grucker D. Elecsys insulin assay: free insulin determination and the absence of cross-reactivity with insulin lispro. Clin. Chem. 2001, 47(3):602-605.
11. Glenn C., Armston A. Cross-reactivity of 12 recombinant insulin preparations in the Beckman Unicel DxI 800 insulin assay. Ann. Clin. Biochem. 2010, 47(Pt 3):264-266.
12. Moriyama M., Hayashi N., Ohyabu C., Mukai M., Kawano S., Kumagai S. Performance evaluation and cross-reactivity from insulin analogs with the ARCHITECT insulin assay. Clin. Chem. 2006, 52(7):1423-1426.
13. Peterman S., Niederkofler E.E., Phillips D.A., Krastins B., Kiernan U.A., Tubbs K.A., et al. An automated, high-throughput method for targeted quantification of intact insulin and its therapeutic analogs in human serum or plasma coupling mass spectrometric immunoassay with high resolution and accurate mass detection (MSIA-HR/AM). Proteomics 2014, 14(12):1445-1456.
14. Scarlett J.A., Mako M.E., Rubenstein A.H., Blix P.M., Goldman J., Horwitz D.L., et al. Factitious hypoglycemia. Diagnosis by measurement of serum C-peptide immunoreactivity and insulin-binding antibodies. N. Engl. J. Med. 1977, 297(19):1029-1032.
15. Bolli G.B., Hahn A.D., Schmidt R., Eisenblaetter T., Dahmen R., Heise T., et al. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Diabetes Care 2012, 35(12):2626-2630.
16. Joint Formulary Committee. British National Formulary 2013, BMJ Group and Pharmaceutical Press, London. 65 ed.